Jaguar Animal Health (JAGX) Expected to Announce Earnings on Thursday

Jaguar Animal Health (NASDAQ:JAGX) is anticipated to issue its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($52.15) per share and revenue of $4.24 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 28, 2026 at 9:30 AM ET.

Jaguar Animal Health (NASDAQ:JAGX) last issued its quarterly earnings data on Wednesday, May 20th. The biotechnology company reported ($13.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($149.10) by $135.50. The company had revenue of $20.27 million for the quarter, compared to analysts’ expectations of $4.21 million.

Jaguar Animal Health Trading Down 12.2%

NASDAQ JAGX opened at $0.83 on Tuesday. The company’s 50-day moving average price is $2.08 and its 200-day moving average price is $10.56. The stock has a market cap of $500,640.00, a PE ratio of -0.00 and a beta of -0.06. Jaguar Animal Health has a 12 month low of $0.82 and a 12 month high of $92.75.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Wall Street Zen raised shares of Jaguar Animal Health from a “sell” rating to a “hold” rating in a research report on Saturday, May 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.